Buprenorphine SR2

Buprenorphine SR Description  Buprenorphine SR Dosage  Buprenorphine SR Chemistry 

 

Buprenorphine SRis an injectable, patented, sustained-release polymer  system  designed to release Buprenorphine over a 72-hour period.

Indications

Buprenorphine has produced excellent analgesic results in broad clinical applications for cats, dogs, exotic species and laboratory animals. This thebaine derivative provides analgesia for management of perioperative / postoperative pain, as well as painful joint injuries, fractures, tissue inflammation due to infection, tissue necrosis and trauma resulting from wounds. Amelioration of postsurgical pain has been substantiated in a variety of species1.  Due to its long duration of action, it is one of the most widely used opioid analgesics in veterinary clinical practices.2,3,4                             

           Key Features of Buprenorphine SR™

  • Provides sustained release delivery of Buprenorphine in a fully biodegradable liquid polymer matrix                           
  • Provides a consistent 72-hour release profile with consistent drug absorption
  • Provides blood levels greater than 1 nanogram/mL for post operative analgesia
  • Formulation can be injected subcutaneously through a 22-gauge need

 Chemistry and Pharmacology

Common Name: Buprenorphine Hydrochloride

Chemical Name: 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)- alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, hydrochloride, [5alpha, 7alpha (S)]

Buprenorphine is a thebaine derivative with powerful analgesia approximately
twenty-five to forty times as potent as morphine, and its analgesic effect is due to partial agonist activity at μ-opioid receptors (i.e., when the molecule binds to a receptor, it is only partially activated in contrast to a full agonist such as morphine). Buprenorphine also has very high binding affinity for the μ receptor such that opioid receptor antagonists (e.g. naloxone) only partially reverse its effects.

 

 REFERENCES

1. Roughan JV and Flecknell PA. 2002. Buprenorphine: a reappraisal of its antinociceptive effects and therapeutic use in alleviating post-operative pain in animals. Lab Anim 36:322-343.

2. Capner CA, Lascelles BDX and Waterman-Pearson AE. 1999. Current British veterinary attitudes to peri-operative analgesia for dogs. Veterinary Record 458 145:95-99.

3. Dohoo SE and Dohoo IR1996 Factors influencing the postoperative use of analgesics in dogs and cats by Canadian veterinarians.CanVetJ 37:552-56

4. Watson AD, Nicholson A, Church DB and Pearson MR. 1996. Use of anti-inflammatory and analgesic drugs in dogs and cats. Aust Vet J 74:203-210.

 

Data Sheet / Product Info

Meloxicam